Anti-CD40 Antibodies and Methods of Use (Apexigen Patent Grant)

Tue, 21 Apr 2026 14:20:15 +0000
Intellectual Property

USPTO granted US Patent 12,606,632 B2 to Apexigen, Inc. on April 21, 2026. The patent covers high affinity anti-CD40 monoclonal antibodies and related compositions for therapeutic use in cancer and other diseases. Named inventors are Yongke Zhang, Guo-Liang Yu, and Weimin Zhu.